Taking stock of the drug industry, from the lab to the medicine chestAugust 13, 2024Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer Adobe STAT+ | Otsuka prices depression digital therapeutic to make it widely accessible, says it'll lose money Otsuka's pricing of Rejoyn is indicative of a business strategy that acknowledges the challenges faced by digital therapeutics developers. By Mario Aguilar STAT+ | Acelyrin announces layoffs, strategy shift after late-stage trial results for anti-inflammatory drug Phase 3 trial results for izokibep didn't show a clear edge over competing drugs for the skin disorder hidradenitis suppurativa. By Jonathan Wosen Opinion: Aspirin after a broken bone: health equity in a $5 bottle NEJM study showed aspirin was as effective at preventing blood clots after surgery as a far more expensive blood thinner. Why didn't doctors change their ways? By Deborah M. Stein and Robert V. O'Toole Adobe STAT+ | Why U.S. health care cybersecurity laws are better at protecting a corpse's privacy than patients' lives Current cybersecurity laws prioritize health data over patient safety but the industry and regulators don't agree on the best way forward. By Brittany Trang More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2024, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments